Wire flash
Xinhua Pharmaceutical subsidiary obtains registration certificate for Donepezil orally disintegrating tablets
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 20, Xinhua Pharmaceutical's subsidiary received a registration certificate for Donepezil Hydrochloride Orally Disintegrating Tablets, a prescription drug classified as Chemical Drug Category 4. The drug is indicated for the treatment of mild, moderate, or severe Alzheimer's disease symptoms. According to statistics, sales of donepezil formulations in Chinese public medical institutions in 2025 are estimated at approximately 620 million yuan. The successful registration is expected to enrich the company's product portfolio in the central nervous system field and enhance its overall competitiveness. In mid-2026, Xinhua Pharmaceutical reported revenue of 4.358 billion yuan and net profit attributable to shareholders of 149 million yuan. The article was sourced from Caizhongshe.
Source report
Here is the rewritten news content in clean, professional English Markdown.
Xinhua Pharmaceutical Obtains Drug Registration for Donepezil Hydrochloride Tablets
Date: September 20
Xinhua Pharmaceutical has announced that it has received a Drug Registration Certificate for Donepezil Hydrochloride Tablets (5mg) from the National Medical Products Administration.
The drug is indicated for the symptomatic treatment of mild, moderate, or severe Alzheimer's disease. It is classified as a prescription drug and falls under Chemical Drug Category 4.
According to market data, sales of donepezil formulations in China's public medical institutions are estimated to be approximately CNY 620 million in 2025.
The successful registration of this drug is expected to enrich the company's product portfolio in the central nervous system (CNS) therapeutic area and enhance its overall competitiveness.
In the first half of 2026, Xinhua Pharmaceutical reported revenue of CNY 4.358 billion and net profit attributable to shareholders of CNY 149 million.
Source: CBN (China Business News)
Source
东方财富网-A股公司Eastern
Part of this Story
Xinhua Pharmaceutical subsidiary gains China approval for Alzheimer’s drug Donepezil tablets